GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Tibet Rhodiola Pharmaceutical Holding 600211.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

39.51

-2.13%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Tibet Rhodiola Pharmaceutical Holding

Its shares trade on Shanghai under the ticker 600211.SS. It has been listed since 21 July 1999. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.95bn and net income of CN¥937.9m. At that date it held total assets of CN¥6.27bn and shareholders' equity of CN¥3.80bn.

Tibet Rhodiola Pharmaceutical Holding Co. engages in the manufacture and wholesale of pharmaceutical products. The company is headquartered in Lhasa, Xizang. The firm operates its businesses through the distribution of proprietary drug products, as well as the processing of pharmaceuticals and others. The firm conducts its businesses primarily in South China, North China, East China, Central China and overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Providers & Services
Listed since
21 Jul 1999
Employees
615
Website
xzyy.cn ↗

Leadership

Pay as last reported

  • Mr. Dabin ChenChairman of the Board, since 2015CN¥1.7m
  • Mr. Yucheng ZhouVice Chairman of the Board, since 2009CN¥1.2m
  • Mr. Jun ChenChief Financial OfficerCN¥469,700
  • Mr. Yuandong GuoGeneral Manager, Director, since 2014CN¥1.7m
  • Ms. Lan LiuDeputy General Manager, Secretary of the BoardCN¥673,000
  • Mr. Bo TangDeputy General ManagerCN¥512,100
  • Mr. Yongguo YuanDeputy General Manager
  • Ms. Yufang LiDirectorCN¥6,700
  • Mr. Lieyi MaDirectorCN¥80,000
  • Ms. Sanyan WuDirectorCN¥80,000
  • Mr. Jiankun LinIndependent Director
  • Mr. Jiayun ManIndependent DirectorCN¥180,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Lhasa, Xizang, with a focus on pharmaceutical manufacturing and wholesale.
  • Employs 615 full-time employees, indicating a stable workforce.
  • Operates through distribution of proprietary drug products and pharmaceutical processing.

Weaknesses

  • Relies on distribution of proprietary drug products, which may limit innovation.
  • Primarily operates in specific Chinese regions and overseas markets, potentially limiting market reach.
  • No information provided on financial performance or market share.

Opportunities

  • Expanding into new markets beyond South China, North China, East China, and Central China.
  • Growing demand for pharmaceutical products in overseas markets.
  • Potential for increased market share through innovation in pharmaceutical processing.

Threats

  • Dependence on specific regional markets may expose the company to regional economic fluctuations.
  • Competition from other pharmaceutical companies in the same sectors.
  • Lack of detailed financial data may hinder strategic planning and investor confidence.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.